Leukemia Research
Volume 28, Issue 8 , Pages 785-790 , August 2004

The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

  • Joan van den Bosch

      Affiliations

    • Department of Haematology, Leyenburg Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    • ,
  • Michael Lübbert

      Affiliations

    • Department of Haematology/Oncology, University of Freiburg Medical Centre, Freiburg, Germany
    • ,
  • Gregor Verhoef

      Affiliations

    • Department of Internal Medicine, University Hospital Grootziekengasthuis, Leuven, Belgium
    • ,
  • P.W Wijermans

      Affiliations

    • Department of Haematology, Leyenburg Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-70-3592556; fax: +31-70-3592209.

Received 11 August 2003 ,Accepted 27 November 2003.

References 

  1. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk. Res. 2003;27(2):95–120
  2. Negrin RS, Haeuber DH, Nagler A, Olds L, Donlon T, Souza LM, et al.  Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann. Intern. Med. 1989;110:976–984
  3. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68–75
  4. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al.  International scoring systems for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088
  5. Webb JJ, Anderson KC. Risks, costs and alternatives to platelet transfusion. Leuk. Lymphoma. 1999;34:71–84
  6. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br. J. Cancer. 1991;64:144–148
  7. Wijermans PW, Krulder JWM, Huygens PC, Neve P. Continous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndromes. Leukemia. 1997;11:1–5
  8. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al.  Low dose 5-aza-2-deoxycytidine, a DNA-hypomethylating agent for the treatment of high-risk myelodysplastic syndromes: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000;18:956–962
  9. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al.  Cytogenetic responses in high-risk myelodysplastic syndromes following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 2001;114:349–357
  10. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al.  Report of an international working group to standardise response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  11. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al.  Randomised controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J. Clin. Oncol. 2002;20:2429–2440
  12. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I–II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-cancer Drugs. 1997;8:358–368
  13. Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, et al.  5-Aza-2′-deoxycytidine and foetal haemoglobin induction in sickle cell anaemia. Blood. 2000;96:2379–2384
  14. Adams JA, Liu Yin JA, Brereton ML, Briggs M, Burges R, Hyde C. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryocytes in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br. J. Haematol. 1997;99:139–146
  15. Faulhaber M, Wormann B, Ganser A, Verbeek W. In vitro response of myelodysplastic megakaryocytes to megakaryocyte growth and development factor (MGDF). Ann. Hematol. 2002;81:695–700
  16. Wang W, Matsuo T, Yoshida S, Mori H, Miyazaki Y, Kuriyama K, et al.  Colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. Leukemia. 2000;14:1751–1756
  17. Ogata K, Tamura H. Thrombopoietin and myelodysplastic syndrome. Int. J. Hematol. 2000;72:173–177
  18. Hellstrom Lindberg E, Kanter-Lewensohn L, Nichol J, Ost A. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology, Scandinavian MDS group Sweden and Norway. Br. J. Haematol. 1999;105:966–973
  19. Zwierzina H, Rollinger Holzinger I, Nuessler V, Herold M, Meng YG. Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes. Leukemia. 1998;12:59–64
  20. Hoffmann WK, Kalina U, Kosschmieder S, Seipelt G, Hoelzer D, Ottmann OG. Defective megakaryocytic development in myelodysplastic syndrome. Leuk. Lymphoma. 2000;38:13–19
  21. Daskalakis M, Nguygen TT, Nguen C, Guldberg P, Kohler G, Wijermans PW, et al.  Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (Decitabine) treatment. Blood. 2002;100:2957–2964
  22. Teofili L, Martini M, Di Mario A, Rutella S, Urbano R, Luongo M, et al.  Expression of p15 (ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoiesic progenitors. Blood. 2001;98:495–497
  23. Kalina U, Hofman WK, Koschmieder S, Wagner S, Kauschat D, Hoelzer D, et al.  Alteration of c-mpl-mediated signal transduction in CD 34 (positive) cells from patients with myelodysplastic syndromes. Exp. Hematol. 2000;28:1158–1163

PII: S0145-2126(03)00413-2

doi: 10.1016/j.leukres.2003.11.016

Leukemia Research
Volume 28, Issue 8 , Pages 785-790 , August 2004

Article Tools

* Image Usage & Resolution